Laboratory Co. of America Holdings (NYSE:LH – Get Free Report) CAO Peter J. Wilkinson sold 1,384 shares of Laboratory Co. of America stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $210.71, for a total transaction of $291,622.64. Following the completion of the transaction, the chief accounting officer now directly owns 2,087 shares in the company, valued at approximately $439,751.77. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Laboratory Co. of America Trading Down 0.2 %
LH traded down $0.32 during midday trading on Monday, hitting $211.40. The company’s stock had a trading volume of 268,924 shares, compared to its average volume of 758,988. The company has a current ratio of 1.36, a quick ratio of 1.20 and a debt-to-equity ratio of 0.57. The firm has a market cap of $17.95 billion, a P/E ratio of 28.30 and a beta of 1.07. The firm has a 50-day moving average price of $203.27 and a two-hundred day moving average price of $212.75. Laboratory Co. of America Holdings has a 52-week low of $174.20 and a 52-week high of $222.33.
Laboratory Co. of America (NYSE:LH – Get Free Report) last issued its earnings results on Thursday, October 26th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.37 by $0.01. Laboratory Co. of America had a return on equity of 14.09% and a net margin of 4.88%. The business had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same quarter in the previous year, the business earned $4.68 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. On average, research analysts anticipate that Laboratory Co. of America Holdings will post 13.58 earnings per share for the current year.
Laboratory Co. of America Dividend Announcement
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Credit Suisse Group dropped their price objective on shares of Laboratory Co. of America from $247.41 to $231.00 and set an “outperform” rating on the stock in a report on Wednesday, August 2nd. TheStreet cut shares of Laboratory Co. of America from a “b-” rating to a “c” rating in a research report on Thursday, October 26th. Morgan Stanley reduced their target price on shares of Laboratory Co. of America from $285.00 to $260.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. Truist Financial reiterated a “buy” rating and issued a $270.00 target price on shares of Laboratory Co. of America in a research report on Friday, September 15th. Finally, StockNews.com assumed coverage on shares of Laboratory Co. of America in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $243.67.
Hedge Funds Weigh In On Laboratory Co. of America
A number of institutional investors and hedge funds have recently bought and sold shares of LH. Roundview Capital LLC grew its position in shares of Laboratory Co. of America by 1.6% during the first quarter. Roundview Capital LLC now owns 7,793 shares of the medical research company’s stock worth $2,055,000 after buying an additional 124 shares in the last quarter. LSV Asset Management lifted its stake in Laboratory Co. of America by 1.2% in the first quarter. LSV Asset Management now owns 34,800 shares of the medical research company’s stock valued at $9,175,000 after buying an additional 400 shares during the last quarter. Synovus Financial Corp lifted its stake in Laboratory Co. of America by 105.7% in the first quarter. Synovus Financial Corp now owns 1,654 shares of the medical research company’s stock valued at $441,000 after buying an additional 850 shares during the last quarter. Cibc World Market Inc. bought a new stake in Laboratory Co. of America in the first quarter valued at $213,000. Finally, Sei Investments Co. lifted its stake in Laboratory Co. of America by 18.9% in the first quarter. Sei Investments Co. now owns 89,167 shares of the medical research company’s stock valued at $23,543,000 after buying an additional 14,186 shares during the last quarter. Hedge funds and other institutional investors own 89.37% of the company’s stock.
Laboratory Co. of America Company Profile
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.
- Five stocks we like better than Laboratory Co. of America
- Dividend Tax Calculator
- The most upgraded stocks in November have two things in common
- Options Trading – Understanding Strike Price
- Monday.com rocked earnings like it’s the weekend
- What Is Dividend Yield and How Do You Calculate It?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.